{"url_path":"/sec/olma/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1750284/0001193125-26-218156-index.html","accession_number":"0001193125-26-218156","cik":"0001750284","ticker":"OLMA","issuer_name":"Olema Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1750284/0001193125-26-218156-index.html","primary_entity_key":"0001750284","primary_entity_name":"Olema Pharmaceuticals, Inc."},"word_count":176,"has_tables":true,"body_markdown":"# Item 5. Other Information.\n\n \n\nTrading Plans or Rule 10b5-1 Trading Plans\n\nDuring the quarter ended March 31, 2026, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nName\n\nPosition\n\nAction\n\nDate of Adoption/\nTermination\n\nType of Trading Arrangement\n\nExpiration Date\n\nTotal Shares of Common Stock to be Sold***\n\nRule 10b5-1*\n\nNon-Rule 10b5-1**\n\nSean Bohen, M.D., Ph.D.\n\nPresident and Chief Executive Officer\n\nAdoption\n\nMarch 3, 2026\n\nX\n\n \n\n \n\nJune 8, 2027\n\nUp to 705,000\n\n* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.\n\n** \"Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.\n\n*** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 trading arrangement. The number of shares to be sold was dependent on the satisfaction of certain conditions as set forth in the written plan.\n\n \n\n \n\n \n\n113\n\n[Table of Contents](#toc_page)"}